ASH 2017: CAR T-Cell Therapy in Heavily Pretreated Patients With Myeloma
MCRI Provides Funding for Novel Multiple Myeloma Research
Limiting Antigen Escape in Patients With Relapsed Multiple Myeloma
Dose-Escalation Study of CLR 131 in Relapsed or Refractory Multiple Myeloma
Differences in Genetic Mutations in Blacks and Whites With Multiple Myeloma
Venetoclax Combination Therapy for Relapsed or Refractory Multiple Myeloma
Can Type of Myeloma Influence Response to Monoclonal Antibodies?
Multiple Myeloma Precancerous Disease and African Americans
Relapsing/Refractory Multiple Myeloma in a High-Risk Patient: Efficacy With Monoclonal Antibody Therapy as Part of Triple Therapy
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Role of Proteasome Inhibitor Therapy in a Patient with High-Risk Relapsing Multiple Myeloma
Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?
Mayo Clinic Cancer Center
Huntsman Cancer Institute at the University of Utah
Moffitt Cancer Center
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
What is a JNCCN Spotlight?
The Leukemia and Lymphoma Society
NCCN Guidelines for Patients: Multiple Myeloma
Multiple Myeloma Research Foundation (MMRF)
NCCN-Funded Clinical Trials: Find a Clinical Trial